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Introduction
Non-invasive prenatal testing (NIPT) is a technique first developed
in the early 1990’s that enables testing of a fetus for genetic conditions,
based on a sample of maternal blood [1]. Small fragments of
extracellular DNA from both mother and fetus are present in maternal
plasma, and by excluding fragments of maternal origin, the fetus can
be tested for sex, aneuploidy and some specific genetic conditions [2].
The main benefits of this type of fetal testing over amniocentesis or
chorionic villus sampling are the removal of any risk of miscarriage
due to invasive testing and obtaining results in the first trimester [2].
There are some differences in the contexts in which NIPT can be
used to determine the chance of the fetus being affected by a genetic
condition. In some families, there is a known genetic condition that
could be inherited by the fetus. Examples of this type of condition are
cystic fibrosis and achondroplasia [short-limbed dwarfism). In these
families, the genetic mutation is usually known of before pregnancy
and the prospective parents may have been considering prenatal
testing for some time. In a different context, pregnant women may be
offered NIPT for aneuploidy (including trisomy 21). All women in the
general population have a chance of having a fetus affected by trisomy
21, and testing may therefore be offered on a population basis. Women
in this group may not have ever considered fetal testing prior to being
informed about it by the health professional involved in their care
during pregnancy. The extent to which prenatal testing had been
considered prior to pregnancy could seriously influence the level of
informed consent for the test.
In a review of factors affecting the use of NIPT [3], overall both
patients and professionals viewed the use of NIPT positively. Women
felt it empowered them to have testing without the threat of
miscarriage, and the earlier result enabled them to have a termination
at an earlier stage in the pregnancy. However, there were concerns
expressed that the ease of giving a sample might influence women to
have tests for reasons that the participants felt were not justified. Moral
and ethical concerns about increased use of testing and termination
were more likely to be expressed by those in the general population
who had not necessarily considered the test in a personal context.
However, it was noticeable that in most studies the views of men,
particularly prospective fathers, were not sought.
These issues were examined in detail in a recent study of men and
women who were carriers of autosomal recessive conditions [4]. All of
the participants were at risk of having a child with a serious genetic
condition: many of them had affected children or had lost children or
pregnancies. In that study, there was again support for the use of NIPT,
for many of the same reasons unearthed in the systematic review.
However, participants emphasised that even if the test was easy, it was
the results that had to be dealt with. They believed that making
decisions (about the future of the pregnancy) based on those results
could be very difficult and some people accepting the test may not
appreciate that. They also felt that while it was ultimately the woman’s
decision to have the test, both parents should be involved in such an
important and potentially life-changing process.
The ‘take home’ message from the research is that while there are
considerable benefits accruing from the development of NIPT, health
professionals have a duty to ensure that informed consent is given, and
this involves having a conversation about the impact of the results and
potential decisions to be made, based on those results The
responsibility for offering these types of tests will lie with different
groups of health professionals, depending on the purpose of the test
and the health service structure in each country. For example, tests for
single gene disorders where the fetus is known to be at high risk
(usually 25% or 50% chance of being affected, depending on the
disorder) will often be discussed by specialist in genetic services, either
medical geneticists or genetic counsellors or by fetal medicine
specialists. These professionals have extensive experience at offering
prenatal tests in a non-directive manner. However, it may be that tests
for aneuploidy are offered by midwives, obstetricians or family
practitioners, in which case they may have less experience in this
context. In fact, previous research has shown that many midwives lack
the confidence and knowledge to offer prenatal screening for trisomy
21[5]. There must therefore be concern about the ability of health
professionals to offer NIPT to prospective parents in a way that
informs them appropriately and enables them to make informed
decisions. It is important that parents recognise that they have a choice
to decline testing or to accept testing to prepare themselves for the
birth of an affected baby. Testing should not be framed simply as a
route to termination of an affected pregnancy, although this is a
decision that will be the most appropriate one for some parents.
We would suggest that the conversation about NIPT should include
key information about the test, the possibility of false negative or false
positive results and, where relevant, the possible need for an invasive
test to confirm the diagnosis. However, in addition, parents should be
forewarned about the possible implications of the results. One way in
which this can be done is to ask parents to try to consider their
potential reactions to both types of possible results: a result indicating
there is minimal risk of the fetus being affected and a result showing
there is a very high likelihood that the fetus is affected. The question’
What do you think your options might be, based on a high risk result?’
may help to clarify why they are doing the test and their possible
reactions to the outcome. By making the possible outcomes more
concrete for parents, the health professional can facilitate them to
consider the test and the result in the context of their own beliefs and
values.
Non-invasive prenatal testing has the potential to benefit a great
many parents who wish to find out more about the genetic status of
their fetus but wish to minimise any risks involved in testing. It is
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essential that policies regarding NIPT are put in place to guide both
parents and health professionals, and that discussion of the ethical
issues occurs at societal level. Increasing public awareness of this type
of testing will help to prepare prospective parents for decision-making,
but ultimately health professionals have a duty to ensure that they are
able to consider both the short and long term implications of any
decision they make.
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